HEPATOCELLULAR CARCINOMA: AN UPDATE HUBERT E

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

BLUM H.E.; SPANGENBERG H.CH.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: ARCHIVES OF IRANIAN MEDICINE Year:2007 | Volume:10 | Issue:3 Page(s): 361-371

Download Full-Text

View:

379

Download:

409

Cites:

Information Journal Paper

Title

HEPATOCELLULAR CARCINOMA: AN UPDATE HUBERT E

Author(s)

BLUM H.E. | SPANGENBERG H.CH. | Issue Writer Certificate

Keywords

CHEMOTHERAPY

GENE THERAPY

IMMUNE THERAPY

LIVER TRANSPLANTATION

PERCUTANEOUS ETHANOL INJECTION

Abstract

Hepatocellular carcinoma is one of the most common malignant tumors worldwide. The major etiologies and risk factors for HCC development are well-defined and some of the multiple steps involved in hepatocarcinogenesis have been elucidated in recent years. Despite these scientific advances and the implementation of measures for early hepatocellular carcinoma detection in patients at risk, patient survival has not yet significantly improved during the last three decades. This is in part due to the advanced stage of the disease at the time of diagnosis, and in part due to the limited therapeutic options. These fall into five main categories: 1) surgical interventions, including LIVER TRANSPLANTATION; 2) percutaneous interventions, including ethanol injection and radiofrequency thermal ablation; 3) transarterial interventions; 4) radiation therapy; and 5) drugs as well as gene and immune therapies. While surgery and percutaneous as well as transarterial interventions are effective in patients with limited disease (1–3 lesions, <5 cm in diameter) and compensated underlying liver disease (cirrhosis Child A), at the time of diagnosis, more than 80% of patients present with multicentric hepatocellular carcinoma and advanced liver disease or comorbidities that restrict the therapeutic measures to best supportive care. Therefore, early diagnosis, the development of novel systemic therapies for advanced disease and hepatocellular carcinoma prevention are of paramount importance. New technologies, including gene expression profiling and proteomic analyses, should allow to further elucidate the molecular events underlying hepatocellular carcinoma development and to identify novel diagnostic markers as well as therapeutic and preventive targets.

Cites

No record.

References

No record.

Cite

APA: Copy

BLUM, H.E., & SPANGENBERG, H.CH.. (2007). HEPATOCELLULAR CARCINOMA: AN UPDATE HUBERT E. ARCHIVES OF IRANIAN MEDICINE, 10(3), 361-371. SID. https://sid.ir/paper/280242/en

Vancouver: Copy

BLUM H.E., SPANGENBERG H.CH.. HEPATOCELLULAR CARCINOMA: AN UPDATE HUBERT E. ARCHIVES OF IRANIAN MEDICINE[Internet]. 2007;10(3):361-371. Available from: https://sid.ir/paper/280242/en

IEEE: Copy

H.E. BLUM, and H.CH. SPANGENBERG, “HEPATOCELLULAR CARCINOMA: AN UPDATE HUBERT E,” ARCHIVES OF IRANIAN MEDICINE, vol. 10, no. 3, pp. 361–371, 2007, [Online]. Available: https://sid.ir/paper/280242/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops